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Abstract
The number of people taking statins is increasing across the globe, highlighting the importance of fully understanding
statins’ effects on the cardiovascular system. The beneficial impact of statins extends well beyond regression of
atherosclerosis to include direct effects on tissues of the cardiovascular system (‘pleiotropic effects’). Pleiotropic effects on
the cardiac myocyte are often overlooked. Here we consider the contribution of the caveolin protein, whose expression and
cellular distribution is dependent on cholesterol, to statin effects on the cardiac myocyte. Caveolin is a structural and
regulatory component of caveolae, and is a key regulator of cardiac contractile function and adrenergic responsiveness. We
employed an experimental model in which inhibition of myocyte HMG CoA reductase could be studied in the absence of
paracrine influences from non-myocyte cells. Adult rat ventricular myocytes were treated with 10 mM simvastatin for 2 days.
Simvastatin treatment reduced myocyte cholesterol, caveolin 3 and caveolar density. Negative inotropic and positive
lusitropic effects (with corresponding changes in [Ca2+]i) were seen in statin-treated cells. Simvastatin significantly
potentiated the inotropic response to b2-, but not b1-, adrenoceptor stimulation. Under conditions of b2-adrenoceptor
stimulation, phosphorylation of phospholamban at Ser16 and troponin I at Ser23/24 was enhanced with statin treatment.
Simvastatin increased NO production without significant effects on eNOS expression or phosphorylation (Ser1177),
consistent with the reduced expression of caveolin 3, its constitutive inhibitor. In conclusion, statin treatment can reduce
caveolin 3 expression, with functional consequences consistent with the known role of caveolae in the cardiac cell. These
data are likely to be of significance, particularly during the early phases of statin treatment, and in patients with heart failure
who have altered b-adrenoceptor signalling. In addition, as caveolin is ubiquitously expressed and has myriad tissue-specific
functions, the impact of statin-dependent changes in caveolin is likely to have many other functional sequelae.
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Introduction
The number of people taking statins will increase as the
threshold for statin prescription in cardiovascular disease preven-
tion continues to decrease across the globe. For example, recent
amendments to ACC/AHA guidelines for statin prescription [1]
mean that 13 million more individuals, and a total of 49% of
adults between 40 and 75, are now eligible for statin therapy in the
US [2]. This, combined with high-dose statin treatment regimes
recommended for some patient groups (e.g. [3]), highlights the
importance of fully understanding statins’ effects on the cardio-
vascular system. Clinical and experimental data support the view
that the impact of statins on the cardiovascular system extends well
beyond lowering serum LDL cholesterol; many of their beneficial
effects can be ascribed to direct actions on tissues of the
cardiovascular system (‘pleiotropic’ effects). Improved endothelial
function and reduced vascular smooth muscle proliferation,
fibrosis, platelet aggregation are just a few of the many pleiotropic
changes which statins have been shown to elicit [4–7]. Surpris-
ingly, little work has focused on direct effects of statins on the
cardiac myocyte.
Pleiotropic effects of statins have often been linked with
depletion of isoprenoid intermediates of the HMG CoA reductase
pathway, particularly farnesyl pyrophosphate (FPP) and geranyl-
geranyl pyrophosphate (GGPP) which modulate signalling by
facilitating membrane targeting of elements including small and
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heterotrimeric G proteins. Endothelial dysfunction, characterised
by reduced bioavailability of NO, is a common finding in
cardiovascular disease and increased NO production with statin
treatment provides an excellent illustration of the breadth of
statins’ pleiotropic effects. Statins alter NO bioavailability by a
number of different isoprenoid-dependent mechanisms including
increased eNOS expression (via Rho stabilisation of eNOS mRNA
[8]), enhanced eNOS activity (via Ras-dependent Akt phosphor-
ylation [9]), reduced NO scavenging (via Rac1-dependent effects
on NADPH oxidase activity [10]).
However, in jumping on the ‘isoprenoid bandwagon’, one factor
which is often overlooked is that alterations in tissue cholesterol
may also make a significant contribution to statins’ pleiotropic
effects. Statins may initially alter tissue cholesterol levels by
limiting de novo cholesterol synthesis. Nevertheless, cellular
cholesterol homeostasis is maintained through transcriptional
regulation, via sterol regulatory elements (SRE), of proteins
involved in the synthesis (HMG CoA reductase), uptake (LDL
receptors), and efflux (scavenger receptor class B type I, ABC
transporters, caveolin) of cholesterol [11]. Whilst any changes in
tissue cholesterol are likely to be normalised to some extent by
transcriptional control, altered expression of cholesterol homeo-
static proteins may have functional consequences. Certainly this is
the case for NO bioavailability. Statin treatment has been shown
to decrease the expression of caveolin 1 in endothelial cells and, as
caveolin is a key inhibitory regulator of eNOS, thereby increase
eNOS activity [12].
As well as its contribution to cholesterol homeostasis, caveolin is
of fundamental importance in most cells as a structural component
of caveolae, invaginated lipid rafts, and as a regulatory scaffold
[13]. Caveolae are required for normal cardiac function: caveolin
3 (Cav3) is the muscle-specific caveolin isoform and Cav3
knockout mice develop hypertrophy and cardiomyopathy [14].
Both decreased and increased expression of Cav3 have detrimen-
tal effects on the heart, illustrating the need to maintain caveolin
expression within strict limits for optimal cardiac function [14,15].
Acute manipulation of caveolae/caveolin binding has demonstrat-
ed that cardiac myocyte contractile function and b adrenoceptor
(AR) responsiveness are exquisitely dependent on caveolae and
caveolin [16–19]. Given all this, the potential impact of statin
treatment on myocyte contractility or the response to sympathetic
stimulation is an important consideration, particularly in patients
with heart failure. Here we address this gap in knowledge by
examining the effect of simvastatin treatment on adult rat
ventricular myocyte function. Simvastatin and atorvastatin are
the most widely used statins because the patents for these drugs
have expired, dramatically reducing the cost of prescription. We
chose simvastatin for our study because its patent expired a decade
before that of atorvastatin (in 2003 in the UK). Our priority was to
use cells which provide a true structural and functional represen-
tation of myocytes in the human heart (i.e. adult ventricular
myocytes). We used a simple model system in which effects of
HMG CoA reductase inhibition on the ventricular myocyte could
be studied in the absence of alterations in cholesterol influx/efflux
or paracrine influences from other cells in the myocardium.
This work shows for the first time that inhibition of cholesterol
synthesis has the capacity to modestly depress basal cardiac inotropy
and enhance lusitropy, whilst increasing b-AR responsiveness. Our
data suggest that these functional changes are due in part to altered
caveolin expression and distribution. However, a contribution from
isoprenoid-dependent effects cannot be excluded.
Results
Simvastatin reduces cellular and caveolar cholesterol
Our study employed a simple experimental model to look
directly at the acute effects of statin treatment on the adult cardiac
myocyte. Our first question was whether culturing myocytes in the
presence of simvastatin reduces cellular cholesterol i.e. does
simvastatin reduce de novo myocyte cholesterol synthesis? In
order to select a concentration of simvastatin which is of clinical
relevance, we considered serum levels of drug, tissue accumulation
and IC50. In man, an oral dose of 40 mg simvastatin gives peak
serum levels of up to 0.1 mM [20], yet therapeutic regimes of high
dose simvastatin (up to 80 mg/day), lead to accumulation in tissue
at levels in excess of this (e.g. 12 mM in stomach, 1 mM in spleen
and testis), because of the lipophilic nature of the drug [21,22].
The IC50 of simvastatin for HMG CoA reductase is 0.1 mM in rat
hepatocytes [23]. In preliminary studies we compared the effect of
1 mM and 10 mM simvastatin treatment on myocyte free
cholesterol indexed using the fluorescent antibiotic filipin. With
1 mM simvastatin cholesterol was significantly reduced (P,0.05)
by 31% after 5 days. A similar level of cholesterol depletion was
achieved by a 2 day treatment with 10 mM simvastatin (by 28%,
P,0.05). In order to minimise genotypic and phenotypic changes
in the adult myocyte which are known to occur in culture and can
have profound effects on myocyte contractility [24], we elected to
study the effects of 10 mM simvastatin after 2 days in all
subsequent experiments. Depletion of cholesterol was apparent
throughout the cell, in both surface membrane and deeper regions
(which include t-tubules) (Fig. 1A). We also assessed total
cholesterol in cell lysates using the Amplex Red assay and saw a
similar degree of cholesterol depletion (P,0.05) in statin-treated
preparations (Fig. 1B). Following fractionation of cell homogenates
on a sucrose density gradient, a selective reduction in cholesterol in
buoyant raft/caveolar fraction 4 was observed (P,0.05; Fig. 1C).
High levels of cholesterol in this fraction may facilitate detection of
changes in cholesterol; we do not exclude the possibility that
simvastatin induces small changes in cholesterol in other fractions
of the cell.
Simvastatin reduces cellular and caveolar Cav3
Next we addressed the question of whether simvastatin affects
the expression of Cav3 - the muscle-specific caveolin isoform.
Cav3 staining in fixed permeabilised cells was reduced by <30%
(P,0.01) following statin treatment (Fig. 2A); depletion of Cav3
was apparent in both surface and t-tubular membranes. In cell
lysates, total Cav3 expression was also reduced (P,0.05) (Fig. 2B).
These data support the view that Cav3 expression may be
regulated via SRE. Of note, direct evidence only exists for SRE-
dependent regulation of the Cav1 isoform e.g. [25]. However,
when we searched 1 KB of DNA, in the 59 flanking region of
Cav3, for SRE binding protein consensus sequences, we identified
4 sites for rat Cav3 (22651, 24401, 27201, 28351 base pair
distances from the transcription start site, with a .85% binding
probability) (http://www.cbrc.jp/research/db/TFSEARCH.
html), providing some support for the concept of SRE control of
Cav3 transcription in this species.
Manipulation of cellular cholesterol also affects Cav3 distribu-
tion in the cell [26,27]. So next we looked specifically at Cav3
distribution within the membrane following sucrose density
gradient fractionation. Statin treatment significantly reduced
Cav3 levels in caveolar buoyant fractions 4 and 5, and increased
levels in non-buoyant fractions 9–12 which represent non-
cholesterol enriched membranes and cytosolic proteins (Fig. 2C).
Thus, simvastatin reduces both cellular and caveolar Cav3, which
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is consistent with demonstrated effects on cholesterol (which binds
Cav3 and regulates its expression/distribution).
Although the focus of our work is the muscle specific Cav3
isoform, some Cav1 is also found in the cardiac myocyte. We
measured levels of Cav1 in cell lysates. There was significant
variability in Cav1 expression between cell populations in the
absence of statin treatment, and a trend (P.0.05) for lower Cav1
expression (normalised to GAPDH) in statin treated cells vs.
controls (6.5762 vs. 8.4463.08; n = 4).
Figure 1. Treatment with 10 mM simvastatin for 48 h reduces
cellular and caveolar cholesterol in the adult ventricular
myocyte. A. Cellular free cholesterol indexed in fixed myocytes
labelled with filipin. Bar graph shows mean fluorescence (arbitrary units,
AU) from n = 48-58 myocytes (from 4 hearts). Representative control
and statin-treated myocytes are shown below. B. Total cholesterol
(normalised to total protein concentration) measured in cell lysates
using the Amplex Red assay (n = 7 hearts). C. Cholesterol distribution
measured in cell lysates following sucrose density gradient fractionation
using the Amplex Red assay. Samples were adjusted to equal protein
concentrations before fractionation (n = 3 hearts). All data are mean 6
S.E.M. * P,0.05, ** P,0.01 vs. control, Student’s t-test.
doi:10.1371/journal.pone.0106905.g001
Figure 2. Simvastatin treatment reduces cellular and caveolar
Cav3. A. Total membrane-bound Cav3 indexed using immunocyto-
chemistry. Bar graph shows mean fluorescence (arbitrary units, AU)
from 59–70 myocytes. Representative control and statin-treated
myocytes are shown below. B. Total cellular Cav3 measured in cell
lysates using Western blotting. Values are normalised to GAPDH. C.
Membrane distribution of Cav3 measured in cell lysates following
sucrose density gradient fractionation using Western blotting. Fractions
4 and 5 are cholesterol-enriched buoyant fractions (BF); fractions 7–12
are non-buoyant fractions (nBF). All data are mean + S.E.M from n = 3–4
hearts. * P,0.05, ** P,0.01 vs. control, Student’s t-test.
doi:10.1371/journal.pone.0106905.g002
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Simvastatin reduces the density of caveolae
Given that simvastatin depletes the myocyte membrane of both
cholesterol and Cav3, the two essential components of caveolae,
we predicted that this would cause a reduction in caveolar density.
Representative electron micrographs of sections of membrane
from control and statin-treated myocytes are shown in Figure 3.
We observed a significant <30% reduction in caveolar density
from 0.8660.11 mm21 membrane in controls to 0.6360.08 mm21
in treated myocytes (P,0.05). Interestingly, we also recorded a
significant reduction in cell capacitance in statin-treated cells
compared with controls (Fig 3C), which is consistent with reduced
electrically-accessible membrane (i.e. ‘open’ caveolae, see [27]).
Simvastatin modulates basal myocyte function
Are statin-induced changes in cholesterol and Cav3 associated
with changes in basal cardiac myocyte function? As shown in
Figure 4, simvastatin treatment significantly reduced (P,0.05)
[Ca2+]i transient amplitude and shortening. Kinetics of [Ca
2+]i
transients and contraction were also modulated by simvastatin.
Most notably, we saw a positive lusitropic effect of statin
treatment; statin-treated cells exhibited a significant reduction in
time to half (t0.5) relaxation which was accompanied by a
corresponding hastening of [Ca2+]i transient decay (Fig. 4A,B).
Simvastatin had no effect on the amplitude of ICa,L (Fig. 4C)
suggesting that effects on [Ca2+]i transient amplitude and
contractility are due to alterations in sarcoplasmic reticulum
(SR) function. Indeed, Figure 4D shows that simvastatin reduced
(P,0.05) both SR Ca2+ load and fractional SR Ca2+ release
indexed using caffeine. Simvastatin’s effects on excitation-contrac-
tion coupling are similar to those reported following caveolae
disruption with the cholesterol-depleting agent methyl-b-cyclo-
dextrin (MBCD); reduced [Ca2+]i transient amplitude and
shortening in MBCD-treated cells was ascribed to reduced
fractional SR Ca2+ release without any change in ICa,L [17].
The impact of simvastatin on basal contractility can be ascribed
to inhibition of HMG CoA reductase because supplementation of
simvastatin-containing culture medium with mevalonate (the
product of HMG CoA reductase) significantly enhanced (P,
0.001) basal shortening compared with simvastatin alone (6.360.7
Figure 3. Simvastatin treatment reduces caveolar density. A. Representative membrane from control and simvastatin-treated cardiac
myocytes. Arrows indicate caveolae. Scale bar represents 200 nm. B. Simvastatin treatment reduced the mean density of caveolae measured in
<330 mm of membrane (n = 9 myocytes from 3 hearts). * P,0.05, Student’s t-test. C. Simvastatin treatment reduced cell capacitance (n = 27–33 cells
from 19 hearts). *** P,0.001 Mann Whitney Rank test.
doi:10.1371/journal.pone.0106905.g003
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vs. 4.060.3% of resting length; n = 34–40 cells) and shortening in
myocytes cultured with simvastatin and mevalonate was not
different (P.0.05) to that in control cells (6.860.5%; n = 41).
Simvastatin enhances b2-AR responsiveness
Cholesterol-dependent disruption of caveolae with MBCD in
the adult ventricular myocyte enhances b2-AR responsiveness and
increases the sensitivity of functional responses to b1-AR
stimulation [16,17,19]. To our knowledge, the only study to date
to investigate the effect of statin treatment on b-AR signalling in
the ventricular myocyte has shown reduced (non-selective) b-AR
responsiveness in neonatal cardiac myocytes treated with atorvas-
tatin in vitro; effects were ascribed to isoprenylation-dependent
effects on Gas [28]. Together this work suggests that simvastatin
has the potential to modulate the way that the adult heart responds
to b-AR stimulation through both cholesterol and isoprenoid-
dependent mechanisms. Therefore we next determined the
consequences of simvastatin treatment for the response to selective
stimulation of b1- and b2-AR. There was no significant difference
(P.0.05) between control and statin-treated myocytes in the
response of shortening or [Ca2+]i transient amplitude to b1-AR
stimulation with 10 or 100 nM isoproterenol (in the presence of
the b2-AR antagonist ICI; Fig. 5A-D). However, the response of
ICa,L to 10 nM isoproterenol was significantly increased (P,0.05)
by 80% in statin-treated cells (Fig. 5E-G). By contrast, statin
treatment markedly enhanced the response of shortening and
[Ca2+]i transient amplitude to selective stimulation of the b2-AR
with 50 and 100 nM zinterol (in the presence of the b1-AR
antagonist CGP; Fig. 6A-D). We saw no significant ICa,L response
to b2-AR stimulation in control cells (as we have reported
previously [19]) (Fig. 6E). The statin-induced increase in b2-AR
inotropic responsiveness could not be ascribed to changes in ICa,L
(Fig. 6F,G). Caveolae compartmentalise cAMP-dependent signal-
ling by facilitating b2-AR coupling to Gai [19]. In order to test
whether enhanced b2-AR responsiveness with statin treatment
could likewise be attributed to effects on Gi, we compared the
effect of abolishing Gi signalling with PTX in control and statin-
treated cells. PTX enhances b2-AR inotropic responses in control
cells (Fig. 6H) to a level comparable with that induced by statin
treatment, and PTX had no impact (P.0.05) on b2-AR responses
in statin-treated cells. Together these data suggest that statin
treatment enhances b2-AR responses by restricting b2-Gi
coupling.
In cells co-cultured with simvastatin and mevalonate, b2-AR
responsiveness to 100 nM zinterol (with CGP) was significantly
reduced (P,0.001) compared with cells cultured with simvastatin
alone (663 vs. 72614% increase in shortening over baseline;
n = 32–37 cells). These data are consistent with enhanced b2-AR
responsiveness being mediated through simvastatin inhibition of
HMG CoA reductase.
We have previously shown that increased b2-AR responsiveness
following caveolae disruption is due to enhanced phosphorylation
of the SR protein phospholamban (PLB) at Ser16, the PKA site
[19]. Figure 7A shows levels of Ser16 phosphorylated PLB (pPLB)
in control and statin-treated samples under basal conditions and
following selective b2-AR stimulation with 100 nM zinterol.
Interestingly, under basal conditions (i.e. in the absence of b2-
AR stimulation) we saw a significant 300% increase (P,0.05) of
pPLB in statin-treated cells compared with controls, which could
explain the faster transient decay and relaxation kinetics in these
cells (see Fig. 4A,B). This was seen in the absence of any difference
(P.0.05) in expression of PLB (1.9560.33 vs. 2.2060.21),
SERCA2a (2.8560.26 vs. 2.2360.27) or in the PLB/SERCA
ratio (0.7360.17 vs. 1.03 vs. 0.17) between control and statin-
treated cells respectively (values normalised to GAPDH; n = 4
hearts). Both groups showed a significant change (P,0.05) in
pPLB with b2-AR stimulation, but the increase in pPLB was
greater in statin treated cells. Troponin I (TnI) is also phosphor-
ylated by PKA at Ser23/24. There was no difference in basal pTnI
between groups, and b2-AR stimulation did not alter pTnI in
control cells. However, in statin-treated cells, b2-AR stimulation
resulted in a 92% increase (P,0.05) in pTnI over basal levels
(Fig. 7B). Together these data suggest that statin treatment
changes the amplitude and spatial characteristics of cAMP-
dependent signalling following b2-AR stimulation.
It is worth highlighting that ventricular myocytes cultured for 2
days show differences in their response to b2-AR stimulation
(notably increases in pPLB, associated with significant lusitropy
which are absent in non-cultured cells) [19]. This suggests a
change in the normal local/global pattern of cAMP-dependent
signalling. Thus, although we used culture conditions which best
preserve myocyte morphology and function, it is impossible to fully
preserve the phenotype of the freshly dissociated myocyte.
Simvastatin increases NO production
Statins have been shown to modulate NO production in a
variety of cell types [9,10,29]. NO modulates basal and
sympathetic regulation of myocyte function [30,31] therefore
NO effects may contribute to observed changes in basal and b-AR
stimulated function following statin treatment. Endothelial NOS
(eNOS) is the primary constitutive NOS in the myocardium,
expressed in both endothelial cells and the cardiac myocyte itself
[32]. Therefore we measured expression of eNOS and its
phosphorylation at the Ser1177 Akt site (p-eNOS) in myocyte
lysates. We were unable to detect nNOS expression in our
myocyte lysate, likely because of very low expression of this
protein. There was no significant difference (P.0.05) in eNOS
expression or in the amount of p-eNOS (i.e. p-eNOS normalised
to GAPDH) between control and statin-treated cells (Fig. 8A,B). A
key regulator of eNOS (and nNOS) is caveolin, which exerts a
tonic inhibitory influence on NOS activity [33,34], therefore NO
production can be regulated in the absence of changes in eNOS
expression or phosphorylation. We measured NO metabolites
(nitrates and nitrites) as an index of NO in medium from myocytes
cultured for 2 days in the presence or absence of simvastatin. In
statin-treated cells NO metabolites were <20% higher than in
controls (P,0.05; Fig. 8C), consistent with enhanced NOS activity
secondary to reduced Cav3 expression.
Figure 4. The effect of simvastatin treatment on shortening, [Ca2+]i handling and ICa,L under basal conditions. A. Representative traces
and mean data of amplitude and kinetics of shortening. Shortening amplitude is expressed as a % of resting cell length. There was no difference in
resting cell length between groups (9762 vs. 10163 mm in control and statin-treated cells respectively). n = 33–41 myocytes from 5 hearts. B.
Representative traces and mean data of amplitude and kinetics of the [Ca2+]i transient. Transient amplitude is expressed in fura-2 ratio units (RU).
There was no difference in diastolic [Ca2+]i between groups (0.7860.01 vs. 0.8060.01 RU in control and statin-treated cells respectively). n = 33–41
cells from 5 hearts. C. Peak ICa,L was measured following a step from 240 to 0 mV. n = 6–8 cells from 3 hearts. D. Sarcoplasmic reticulum (SR) Ca2+
load and fractional SR Ca2+ release. The left side of the panel shows the amplitude of [Ca2+]i transients (expressed as RU) induced by rapid application
of 10 mM caffeine, an index of SR Ca2+ load. On the right, fractional release (the amplitude of the steady-state electrically-stimulated transient/
caffeine-induced transient) is shown. n = 33–36 cells from 4 hearts. * P,0.05; ** P,0.01, Student’s t-test.
doi:10.1371/journal.pone.0106905.g004
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The contribution of cholesterol and isoprenoids to
simvastatin’s effects
In general, the effects of simvastatin on basal and b-AR
stimulated adult myocyte function are very similar to those we
have reported previously when caveolae are disrupted with
MBCD, suggesting that simvastatin is working through cholester-
ol-dependent (caveolar) pathways. However, given the body of
data that show isoprenoid-dependent statin effects in neonatal
cardiac myocyte and non-cardiac cells, we looked at the possible
contribution of isoprenoids to the observed functional effects. Basal
shortening and the inotropic response to b2-AR stimulation were
measured in cells cultured with statins in the presence of FPP and/
or GGPP. Isoprenoid supplementation did not increase (P.0.05)
basal shortening in statin-treated cells (Fig. 9A), thereby ruling out
a role for protein prenylation in depressed basal myocyte function.
There was a trend for reduced b2-AR responsiveness when statin-
treated myocytes were cultured in the presence of either FPP or
GGPP but these differences were not significant (P.0.05; Fig. 9B).
However, when FPP and GGPP were used together, a significant
reduction (P,0.05) in b2 responsiveness was observed. This
suggests that isoprenoid-dependent effects may contribute to
simvastatin’s ability to enhance b2-AR responsiveness.
Discussion
Statin treatment of cultured myocytes is an excellent experi-
mental model in which the concentration of drug and duration of
treatment can be exactly controlled, and contribution from non-
myocytes excluded. In the present study we have treated cells for 2
days with 10 mM simvastatin, a concentration which is widely used
in vitro and shows no evidence of toxicity. Our chosen regime
results in an identical depletion of cellular cholesterol to that seen
following a 5 day treatment with 1 mM simvastatin, yet allows us to
best preserve the adult myocyte phenotype.
Until recently, very little was known about cholesterol
homeostasis in the cardiac muscle cell [35]. However, recent
work has demonstrated that (neonatal) ventricular myocytes
control cholesterol predominantly through cholesterol efflux rather
than internalisation of native or acetylated LDL [11]. These
authors focused on the ABC transporters as cholesterol efflux
pathways, however caveolin has also been linked with cholesterol
efflux to HDL [36,37]. Here we show further evidence for a
cholesterol-dependent control of efflux pathways. Inhibition of de
novo cholesterol synthesis by simvastatin reduced cellular and
caveolar cholesterol in the adult cardiac myocyte and this was, in
turn, associated with a significant depletion of cellular and
caveolar Cav3. Ultimately this change could act to preserve
cellular cholesterol by reducing efflux. However, decreased
caveolin expression has many additional consequences for cardiac
cell function.
Caveolar density was reduced in simvastatin-treated myocytes,
as we would predict from reduced cellular and caveolar levels of
cholesterol and Cav3. Although myocyte cholesterol levels would
tend to normalise with statin treatment in vivo, we predict that the
maintained decrease in cellular caveolin required to effect this
normalisation of cholesterol would be sufficient to reduce the
number of caveolae even in the presence of normal cellular
cholesterol, since caveolin is required for the presence of caveolae
e.g. [14].
Simvastatin-disruption of caveolae was associated with 2
fundamental changes in cardiac myocyte contractility: a decrease
in the degree of shortening and an increase in the rate of
relaxation. Both could be explained by corresponding changes in
the [Ca2+]i transient. Our data suggest that the reduction in
amplitude of [Ca2+]i transient is due to reduced Ca
2+ -induced
Ca2+ release secondary to decreased SR Ca2+ load. The hastening
of Ca2+ transient decay is consistent with the 3-fold increase in
pPLB (without changes in total PLB or PLB/SERCA2a ratio)
measured in statin-treated cells. However, in the absence of other
changes in Ca2+ handling processes, the predicted effect of
enhancing SERCA activity by increased pPLB would be an
increase in SR Ca2+ content, [Ca2+]i transient amplitude and
contractility [38], which is opposite to the observed effect.
Therefore additional statin effects must be responsible for
maintaining SR Ca2+ load at a lower level (perhaps via NO-
induced SR Ca2+ leak, see below). A previous study has reported
increased SERCA, but not PLB, expression using a similar in vitro
treatment regime with 10 mM simvastatin, however these exper-
iments were performed with neonatal ventricular myocytes which
differ structurally and functionally from their adult counterparts
[39].
Here we report no impact of statin treatment on the response to
b1-AR stimulation with 100 nM isoproterenol, but increased ICa,L
and a trend for increased [Ca2+]i transient responses to 10 nM
isoproterenol. This is consistent with enhanced sensitivity of
functional responses to b1-AR stimulation, comparable with data
obtained using MBCD to disrupt myocyte caveolae [16].
Increased adenylyl cyclase activity, by removal of the normal
inhibitory influence of Cav3 [40], may contribute to this effect.
The disparity between consequences of statin treatment for ICa,L
and contraction suggests there may be some selective effect of
statin treatment on extra-junctional L type Ca2+ channels which
are not involved in excitation-contraction coupling (e.g. see [41]).
We also report a marked enhancement of the inotropic response to
b2-AR stimulation in statin-treated cells which mimics that seen
following MBCD treatment [19]. b2-ARs couple sequentially to
Gs and Gi proteins and prevention of Gi coupling enhances b2-
AR responsiveness [17,42]. Statin effects are consistent with
uncoupling of b2-AR and Gi, as simvastatin treatment mimics
abolition of Gi signalling by PTX, and statin-treated cells are
unresponsive to PTX. Further evidence for the impact of
simvastatin on Gi comes from the apparent conversion of a
sarcolemmal/sarcoplasmic reticular confined cAMP-dependent
b2-AR signal in control cells to a global signal which targets the
myofilament protein TnI in statin-treated cells. b2-AR induced
phosphorylation of PLB was also enhanced by statin treatment.
Although myocytes cultured for 2 days do show some differences
in the sensitivity and spatial characteristics of cAMP-dependent
signalling when compared with non-cultured cells, empirically the
effects of statin treatment on protein phosphorylation are
equivalent to that induced by PTX [43].
What is responsible for the sequelae of statin treatment? We
have shown that altered basal and b-AR stimulated function is due
to simvastatin inhibition of HMG CoA reductase inhibition.
Figure 5. The effect of simvastatin treatment on the response to selective b1-AR stimulation. A, B. Representative traces and mean data
showing the response of shortening (expressed as a % of resting cell length) to selective stimulation of b1-AR with 100 nM isoproterenol (Iso) in the
presence of 100 nM ICI 118,551. C, D. Representative traces and mean data of the response of [Ca2+]i transient amplitude to selective b1-AR
stimulation. Data are from 20–30 myocytes from 7 hearts. E, F, G. Representative traces and mean data of the response of ICa,L to selective stimulation
of b1-AR with 10 nM Iso in the presence of ICI 118, 551 (ICI). n = 6–8 myocytes from 3 hearts. * P,0.05, Student’s t-test.
doi:10.1371/journal.pone.0106905.g005
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Altered basal contractility cannot be normalised by supplementa-
tion of culture medium with FPP and GGPP suggesting that this is
an isoprenoid-independent mechanism, whereas supplementation
with FPP and GGPP together does partially revert statin
potentiation of b2-AR responses, suggesting a role for protein
prenylation in this. The fact that both FPP and GGPP
supplementation is required to partially reverse statin-induced
changes in b2-AR responsiveness suggests a complex pathway.
The individual roles for farnesylation and geranylgeranylation
require clarification.
One key mechanism which has been proposed for statin
pleiotropy is increased NO production. Statins can enhance NO
production via depletion of cellular isoprenoids (increased
expression and Akt-dependent phosphorylation of eNOS) [8,9]
and caveolin (increased activity of eNOS and nNOS) [12,34,44].
In the intact myocardium, eNOS is expressed in both endothelial
cells and cardiac myocytes, with higher expression in the former
[32], supporting the view of a strong paracrine influence of
endothelial cell NO on myocyte function. eNOS expression and
Ser1177 phosphorylation were not significantly different between
control and statin-treated groups suggesting a minimal role for
isoprenoid-modulation of eNOS activity in the cardiac cell.
However, our novel finding of decreased caveolin expression in
cardiac cells following statin treatment can account for enhanced
NO production.
It is difficult to interpret the consequences of statin treatment for
cardiac myocyte function observed in the present study simply in
terms of increased NO production, in part because the concen-
tration and location of NO are key factors which determine its
effects (eNOS and nNOS show different subcellular distribution)
and in part because there is no clear consensus from different
laboratories about the effect of NO derived from different sources.
Data from NOS knockout mice suggest that eNOS derived NO
has little effect on basal myocyte contractility, whereas nNOS-
derived NO decreases or increases contractility whilst hastening
relaxation (see [45,46]). The latter phenomena mimic the impact
of statins on basal function reported here. However, the
underlying causes of altered amplitude and kinetics of contraction
Figure 6. The effect of simvastatin treatment on the response to selective b2-AR stimulation. A, B. Representative traces and mean data
of the response of shortening (expressed as a % of resting cell length) to selective stimulation of b2-AR with 100 nM zinterol (ZNT) in the presence of
10 nM CGP20712A. *** P,0.001 vs control. C, D. Representative traces and mean data of the response of [Ca2+]i transient amplitude to selective b2-
AR stimulation. Data are from 24–30 myocytes from 7 hearts. * P,0.05; *** P,0.001 vs control. E, F, G. Representative traces and mean data of the
response of ICa,L to selective stimulation of b2-AR with 100 nM ZNT in the presence of CGP20712A (CGP). Neither control nor simvastatin-treated
myocytes showed a significant response of ICa,L to selective b2-AR stimulation (one sample t-test; data from 13–15 myocytes from 7–8 hearts),
although in every case a robust ICa,L response to 100 mM IBMX was evoked. H. Bar graph shows the effect of pertussis toxin (PTX) treatment on the %
change in shortening in response to b2-AR stimulation with 100 nM ZNT plus CGP. n = 25 myocytes from 5 hearts. * P,0.05; *** P,0.001, 2-way
ANOVA.
doi:10.1371/journal.pone.0106905.g006
Figure 7. Simvastatin treatment modulates phosphorylation of PLB and TnI following b2-AR stimulation. A. Representative
immunoblots and mean data showing levels of Ser16 phosphorylated phospholamban (pPLB) under basal conditions and following b2-AR stimulation
with 100 nM zinterol (ZNT) +10 nM CGP20712A. B. Representative immunoblots and mean data showing levels of Ser23/24 phosphorylated troponin I
(pTnI) under basal conditions and following b2-AR stimulation. Simvastatin had no significant effect (P.0.05) on expression of PLB or TnI. All
phosphorylated protein data are normalised to desmin expression. n = 4 hearts. * P,0.05, 2-way ANOVA.
doi:10.1371/journal.pone.0106905.g007
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differ in some respects between statin treatment and the effects of
nNOS-derived NO. Although nNOS-derived NO may hasten
relaxation by increasing pPLB (secondary to altered phosphatase
activity) [47], which is consistent with our own data in statin-
treated cells, decreased ICa,L has been identified as one mechanism
which subtends impaired contractility as a result of nNOS-derived
NO [48] yet we detected no change in ICa,L following statin
treatment. Furthermore, it is necessary to account for the observed
decrease in SR Ca2+ load with simvastatin treatment, seen despite
elevated pPLB. One possibility is an increase in SR Ca2+ leak via
NO-dependent S-nitrosylation of RyR [49].
In terms of NO effects on b-AR responsiveness, it is generally
agreed that eNOS-derived NO limits the response to non-selective
b-AR stimulation whereas nNOS-derived NO effects are more
diverse (see [50,51]). The marked enhancement of b2-AR
responses in the absence of a change in b1-AR inotropic responses
with statin treatment is not consistent with effects mediated via
NO. Instead, we argue that the impact of statin treatment on b-
AR responsiveness is due directly to disruption of caveolae. Statin
effects mirror MBCD-mediated disruption of caveolae which alters
the amplitude and spread of cAMP-dependent signalling by
limiting cAMP production and promoting phosphatase activity.
We suggest that this occurs because the b2-AR is prevented from
making its usual coupling with Gai [19]. Importantly for the
present study, effects of MBCD on b2-AR responsiveness are
mimicked by inhibiting Cav3 interactions within the myocyte [19].
This implies that changes in caveolin alone (i.e. in the absence of
depletion of cholesterol) heighten the b2-AR cAMP signal.
Figure 8. The effect of simvastatin on eNOS and NO production. A. Total eNOS expression normalised to GAPDH in control and simvastatin-
treated cells. B. Ser1177-phosphorylated eNOS normalised to GAPDH in control and simvastatin-treated cells. Data are from cells from n = 5 hearts. C.
Medium was collected from myocytes cultured for 48 h in the presence or absence of simvastatin. NO metabolites (nitrate/nitrite) were measured by
a fluorimetric assay. Data are [nitrite + nitrate] normalised to values in paired control group (cells from n = 6 hearts). * P,0.05, Student’s t-test.
doi:10.1371/journal.pone.0106905.g008
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Therefore, even after decreased expression of Cav3 promotes
normalisation of cellular cholesterol, statin-dependent effects on
b2-AR responsiveness will be maintained. Figure 10 summarises
potential pathways by which statins may impact on cardiac
myocyte function.
We are aware of the limitations of this work to the clinical
situation where statins are taken long-term in vivo; our aim was to
isolate the direct effects of statins on the cardiac myocyte. In vivo,
contributions from statin effects on other cells of the myocardium
(particularly endothelial cells, a major source of eNOS derived
NO) will be of significance, as well as the long-term compensatory
changes in cholesterol homeostasis. So how do our data relate to
what is known about myocardial function in people taking statins?
There are several reports of improved cardiac function (measured
using echocardiography) following statin treatment [52–54].
However, these were in hypercholesterolaemic patients, so it is
impossible to differentiate between improvement of serum
cholesterol and direct effects on the myocardium. Interestingly, a
recent study has shown that in normocholesterolaemic subjects,
statin treatment improves myocardial function indexed by strain
imaging [55].
On balance, the effects of statins that we observe in this study
are unlikely to compromise cardiac function in healthy individuals.
In patients with heart failure, the observed direct effects of statin
treatment on the cardiac myocyte are likely to be of benefit. A mild
reduction in basal contractility may, similar to b-blockers, improve
cardiac function by reducing myocardial energy expenditure.
Increased myocardial relaxation will improve diastolic filling. In
heart failure, the ratio of b1/b2-AR decreases, and Gi protein
increases [56]. Our findings suggest that statin treatment could
enhance b-2 AR responsiveness by limiting Gi coupling, which
may be beneficial in maintaining the contractile reserve of the
heart. On a cautionary note, this may occur at the expense of the
cardioprotective, anti-apoptotic Gi signalling arm of the b2-AR
[57,58].
Our study presents a fundamental view of the effects of statins
on the cardiac myocyte by treating myocytes in vitro. This
approach has allowed us to show for the first time that statins can
modulate myocyte function via cholesterol-dependent effects on
caveolin expression. Furthermore, as caveolin isoforms are
ubiquitously expressed and have myriad tissue-specific functions,
the impact of statin-dependent changes in caveolin is likely to have
many other functional sequelae.
Methods
Ethics statement
All animal experimentation was carried out in accordance with
the Directive 2010/63/EU of the European Parliament. Adult
male Wistar rats were group housed with 12 h light/dark cycles
and free access to food and water. Animals were used to harvest
tissue only and were sacrificed according to a Schedule 1 method
of the Animal (Scientific Procedures) Act of 1986 at a designated
establishment.
Myocyte isolation and culture
Ventricular myocytes were isolated enzymatically from hearts of
rats (250–280 g) according to the method described by Calaghan
et al. [59]. Cells were cultured using a method based on that
developed by [60] which is designed to minimise changes in the
adult myocyte phenotype during the culture period. In brief,
immediately after isolation, myocytes were plated on laminin and
cultured in serum-free Medium 199 with 5 mM creatine, 5 mM
taurine, 2 mM Na pyruvate, 2 mM L-carnitine plus 0.1 mM
insulin and 2 mg/ml Primocin (Amaxa). Medium was supple-
mented with 10 mM sodium simvastatin (Merck Chemicals Ltd) or
vehicle (0.1% DMSO) for 48 h. As medium lacked LDL and
cholesterol acceptors (apolipoproteins, HDL), any effects of HMG
CoA inhibition on cholesterol influx or efflux pathways (see
Introduction) were minimised. Only adherent (viable) myocytes
were used for subsequent biochemical or functional assays.
Sucrose density gradient fractionation
Myocytes were fractionated using detergent-free methods as
described previously [18]. Adherent myocytes were scraped from
culture wells using 500 mM Na2CO3 (pH 11.0) containing
0.5 mM EDTA and 1% protease inhibitor cocktail (Sigma).
Samples were homogenised (Ultra-Turrax T8; Ika), then sonicated
(Vibra Cell; Sonics) 3 times each for 20 s at full power.
Approximately 2 ml of homogenate was mixed with an equal
volume of 90% sucrose in MES-buffered saline (25 mM MES,
150 mM NaCl, 2 mM EDTA, pH 6.5) to form a 45% sucrose
solution. A discontinuous sucrose gradient was created by layering
Figure 9. Isoprenoid dependence of simvastatin effects on
basal function and the response to b2-AR stimulation. Myocytes
were cultured with simvastatin in the presence of farnesyl pyrophos-
phate (FPP), and/or geranylgeranyl pyrophosphate (GGPP). A. Basal
shortening (as a % of resting cell length). B. % change in shortening in
response to b2-AR stimulation with 100 nM zinterol plus 10 nM
CGP20712A. n = 32–38 myocytes from 7 hearts * P,0.05, 1-way ANOVA.
doi:10.1371/journal.pone.0106905.g009
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on to this a further 4 ml each of 35% and 5% sucrose solution
(MES-buffered saline with 250 mM Na2CO3). Gradients were
centrifuged for 17 h at 280,000 g (Beckman SW40Ti rotor) at
4uC. A total of 12 fractions (each 1 ml) were collected following
fractionation.
Cholesterol measurement
Free cholesterol distribution was imaged in myocytes fixed with
2% paraformaldehyde for 1 h at room temperature, and stained
with filipin solution (50 mg.ml21 with 4% donkey serum in
phosphate-buffered saline) for 1 h at 37uC (see [16,61]). Sections
of approximately 2 mm thickness were acquired by confocal laser
microscopy (Zeiss LSM 510) with excitation at 364 nm and
detection at 385–470 nm. Identical confocal settings were used to
acquire images of control and statin-treated myocytes. Whole-cell
fluorescence was quantified using ImageJ software. Total choles-
terol was measured in cell homogenates before and after
fractionation using the Amplex Red assay (Invitrogen). For
cholesterol levels in unfractionated samples, cholesterol was
normalised to the protein content of each sample. For fractionated
samples, to allow comparison of cholesterol distribution, proteins
levels for all samples were normalised prior to fractionation, and
cholesterol measured in equivalent fraction volumes.
Immunocytochemistry
The distribution of Cav3 (the muscle-specific isoform) in fixed,
triton-permeabilised myocytes was imaged by immunocytochem-
istry as described in [17]. In triton-permeabilised cells, non-
tethered proteins will be dialysed during sample preparation [62],
therefore this method will preferentially label membrane-tethered
Cav3. Identical confocal settings were used to acquire images of
control and statin-treated myocytes.
Western blotting
Protein expression in cell lysates before and after fractionation
was measured by Western blotting as described in [59]. Desmin
and GAPDH were used to ensure equal protein loading of cell
lysate samples; statin treatment had no effect (P.0.05) on
expression of either protein (desmin 6.760.59 vs 7.0361.24
[n = 4] and GAPDH 6.2660.23 vs 6.1660.27 [n = 5] arbitrary
units, AU, for control and statin-treated cells respectively). For
fractionated samples, equal volumes of fractions were loaded onto
SDS-gels and band density normalised to the sum of the band
density in all fractions.
Figure 10. Statin effects on the cardiac myocyte. The main cholesterol synthesis pathway is highlighted in grey. The impact of statin inhibition
of HMG-CoA reductase, the rate limiting step of cholesterol synthesis, is shown. Statins limit production of cholesterol and isoprenoid intermediates
(FPP, GGPP). The latter are responsible for post-translational modification of a number of proteins including those of the small G protein family (Ras,
Rho, Rac). The potential roles of isoprenoid- and cholesterol-dependent changes in modulating cardiac myocyte function are listed. From the present
study, bold text indicates established effects, whereas grey text denotes effects which have been eliminated. ROS reactive oxygen species (which
reduce bioavailable NO); PP phosphatase; AC adenylyl cyclase. See Discussion for detailed mechanisms and references.
doi:10.1371/journal.pone.0106905.g010
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Electron Microscopy
Myocytes were fixed overnight with 2.5% glutaraldehyde, post-
fixed using 1% osmium tetroxide and dehydrated through an
ethanol series. Myocytes were embedded in araldite, sectioned and
stained with 20% uranyl acetate (30 min) followed by Reynolds
lead citrate (30 min). Sections were visualised using a JEOL 1200
transmission electron microscope. Caveolae were defined as either
50–150 nm flask-shaped invaginations in the surface membrane or
sealed circular vesicles of the same size within 300 nm of the
sarcolemma [27].
Shortening and [Ca2+]i
Shortening and [Ca2+]i were measured in fura-2 loaded
myocytes field-stimulated at 0.5 Hz (22–24uC) in HEPES-based
physiological solution containing (mM): NaCl 137; KCl 5.4;
NaH2PO4 0.33; MgCl2 0.5; HEPES 5; glucose 5.5; CaCl2 1
(pH 7.4) (Cairn Research Optoscan monochromator; Ionoptix
Cell Contractility system). Parameters were measured under basal
conditions and following selective stimulation of b1 or b2 ARs.
Recordings were taken at the peak steady-state response (<5 min)
following application of agonist.
In order to assess sarcoplasmic reticular (SR) Ca2+ load and
fractional SR Ca2+ release, electrically-stimulated Ca2+ transients
were recorded at steady state, stimulation was switched off and
caffeine (10 mM) was applied 10 s later via a local perfusion
device. SR Ca2+ load was indexed as the amplitude of the caffeine-
stimulated Ca2+ transient. Fractional SR Ca2+ release was
calculated from the ratio of electrically-stimulated to caffeine-
stimulated Ca2+ transient amplitude.
Electrophysiology
ICa,L was measured by voltage clamp, as described by [16].
Microelectrode resistances were between 1 and 2 MV when filled
with intracellular solution containing (in mM) CsCl 130, TEA-Cl
20, EGTA 5, MgATP 5, TrisGTP 0.06, and HEPES 5 (pH 7.2)
Cells were clamped at a holding potential of 280 mV. A 50 ms
pre-pulse to 240 mV was used to inactivate INa, followed by
100 ms test pulse to 0 mV to activate ICa,L. Changes in ICa,L
magnitude were monitored by repeating this protocol once every
5 s.
Drug treatments
b1-AR stimulation was achieved with 10 and 100 nM
isoproterenol in the presence of the b2 antagonist ICI 118,551
(ICI; 100 nM). Selective b2-AR stimulation was achieved with 50
and 100 nM zinterol (Tocris) in the presence of the b1 antagonist
CGP20712A (CGP; 10 nM). Myocyte populations used to
measure phospho-protein responses were field-stimulated during
b-AR stimulation. At 5 min, perfusion buffer was rapidly aspirated
and replaced with Laemmli sample buffer containing protease
inhibitor cocktail (Roche) and phosphatase inhibitor cocktail
(Thermo Fisher Scientific).
For experiments using pertussis toxin (PTX) to disable Gai, cells
were treated with 1.5 mg.ml21 PTX for 3 h at 37uC. To determine
the contribution of HMG CoA reductase inhibition and depletion
of isoprenoids to basal and b-AR responses, mevalonate (100 mM),
FPP and/or GGPP (10 mM) were added to statin-containing
medium at the start of the 48 h culture period. For these protocols,
shortening was measured in the absence of fura-loading.
Measurement of NO metabolites
Quantification of nitrite and nitrate levels in culture medium
was achieved using a method outlined by Nussler et al. [63].
Briefly, isolated myocytes from each heart were split into two
populations and cultured at equal density. Samples of culture
medium were taken after 48 h and ultra-filtrated using Centrisart
1 columns with a molecular weight cut-off of 10 kDa (Sartorius
#12329E). Nitrate pools from resulting ultra-filtrates were
converted to nitrite with nitrate reductase and the total nitrite
concentration of each sample was determined using 2,3-diamino-
napthalene, as described [63].
Reagent suppliers
All reagents were from Sigma Chemical Co. unless otherwise
stated. Antibodies used for Western blotting/immunocytochemis-
try: Cav 3 #610420 (1:2500/1:100), Cav1 #610406 (1:2500),
eNOS #610296 (1:1000), Ser1177 phosphorylated eNOS #
612392 (1:1000) (BD Biosciences), phospholamban #A010-14
(1:5000), Ser16 phosphorylated PLB #A010-12 (1:2000), SERCA
#A010-23 (1:2000) (Badrilla), TnI #4002 (1:1500), Ser22,23
phosphorylated TnI #4004 (1:1500) (Cell Signaling Technology),
desmin #ab8592 (1:1000) (Abcam), GAPDH #G9545 (1:100,000)
(Sigma).
Statistics
Results are expressed as mean 6 S.E.M of n observations.
Where experiments were performed on individual cells, these were
from at least 3 different hearts. Statistical analysis was performed
using the Student’s t-test, Mann-Whitney Rank test, one way- or
two way-ANOVA (with post-hoc analysis by the Tukey test), as
appropriate.
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